Regenxbio price target lowered to $34 from $36 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $34 from $36 and keeps a Buy rating on the shares following the Q4 ...
Sarepta news opens door for Regenxbio over risk/benefit profile, says Leerink
Leerink reiterated an Outperform rating and $24 price target on Regenxbio (RGNX) after Sarepta (SRPT) announced a Duchenne muscular dystrophy ...